To examine the effect of JAG1 on cisplatin-resistance, one of the cisplatin-sensitive ovarian cancer cell lines, A2780s, was transiently transfected with JAG1 at variable doses (0.5, 1.0, and 2.0 μg) (Fig. 5A). This evidence concerns the gene JAG1 and ovarian cancer.